Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | EGFR | P00533 | 1/20 | 0.35 |
| ▸ | BTK | Q06187 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.35 |
| ▸ | FABP7 | O15540 | 1/20 | 0.34 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.34 |
| ▸ | ENPP2 | Q13822 | 2/20 | 0.33 |
| ▸ | ATXN2 | Q99700 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | GLA | P06280 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL831925 | 0.85 | TDP1 (0.44) | BTKMAPTKDM4EGAATDP1 | |
| SCHEMBL11028996 | 0.71 | TSHR (0.44) | TSHRBACE1HPGDFABP7FABP5 | |
| SCHEMBL629930 | 0.67 | TSHR (0.59) | TSHRBACE1FABP7FABP5GLA | |
| SCHEMBL15251729 | 0.67 | TSHR (0.59) | TSHRBACE1FABP7FABP5GLA | |
| SCHEMBL20418703 | 0.67 | TSHR (0.59) | TSHRBACE1FABP7FABP5GLA | |
| SCHEMBL7428360 | 0.66 | TSHR (0.45) | TSHRBACE1HPGDFABP7FABP5 | |
| SCHEMBL6259204 | 0.66 | TSHR (0.58) | TSHRBACE1HPGDFABP7FABP5 | |
| SCHEMBL4877662 | 0.66 | TSHR (0.58) | TSHRBACE1HPGDFABP7FABP5 | |
| SCHEMBL10062407 | 0.66 | TSHR (0.58) | TSHRBACE1HPGDFABP7FABP5 | |
| SCHEMBL22127202 | 0.66 | TSHR (0.43) | TSHRBACE1GRIN2BRAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288376-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI (FR) | 2012-10-16 | — | — | US | disclosed |
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2012-05-17 | — | — | US | disclosed |
| US-8143248-B2 | Tricyclic N-heteroaryl-carboxamide derivatives containing a benzimidazole unit, method for preparing same and their therapeutic use | SANOFI-AVENTIS (FR) | 2012-03-27 | — | — | US | disclosed |
| EP-1987010-B1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2010-04-07 | — | — | EP | disclosed |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-02-12 | — | — | US | disclosed |
| EP-1987010-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | Sanofi-Aventis (FR) | 2008-11-05 | — | — | EP | disclosed |
| WO-2007088277-A1 | TRICYCLIC Ν-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122852-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, CYP3A43 | TSHR 1101/4885BACE1 1758/4885EGFR 1505/4885 |
| US-20090042873-A1 | TRICYCLIC N-HETEROARYL-CARBOXAMIDE DERIVATIVES CONTAINING A BENZIMIDAZOLE UNIT, METHOD FOR PREPARING SAME AND THEIR THERAPEUTIC USE | CYP3A5, CYP2C8, PAICS | TSHR 1062/4885BACE1 1986/4885EGFR 1482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.